Paul, Proma; Chandna, Jaya; Procter, Simon; Dangor, Ziyaad; Leahy, Shannon; John, Hima; Bassat, Quique; Bramugy, Justina; Abubakar, Amina; Nasambu, Carophine; +11 more... Libster, Romina; Sanchez Yanotti, Clara; Seedat, Farah; Horváth-Puhó, Erzsebet; Hossain, AKM Tanvir; Rahman, Qazi; Jit, Mark; Newton, Charles; Milner, Kate; Gonçalves, Bronner; Lawn, Joy; (2022) Neurodevelopmental and growth outcomes after invasive Group B Streptococcus in early infancy: A multi-country matched cohort study in South Africa, Mozambique, India, Kenya, and Argentina. EClinicalMedicine. ISSN 2589-5370 https://researchonline.lshtm.ac.uk/id/eprint/4664961 (In Press)
Permanent Identifier
Use this permanent URL when citing or linking to this resource.
https://researchonline.lshtm.ac.uk/id/eprint/4664961
Abstract
BACKGROUND: Data are limited regarding long-term consequences of invasive GBS (iGBS) disease in early infancy, especially from low- and middle-income countries (LMIC) where most cases occur. We aimed to estimate risk of neurodevelopmental impairment (NDI) in children with a history of iGBS disease. METHODS: A multi-country matched cohort study was undertaken in South Africa, India, Mozambique, Kenya, and Argentina from October 2019 to April 2021. The exposure of interest was defined as a history of iGBS disease (sepsis or meningitis) before 90 days of age, amongst children now aged 1.5–18 years. Age and sex-matched, children without history of GBSwere also recruited. Age-appropriate, culturally-adapted assessments were used to define NDI across multiple domains (cognitive, motor, hearing, vision, emotional-behaviour, growth). Pooled NDI risk was meta-analysed across sites. Association of iGBS exposure and NDI outcome was estimated using modified Poisson regression with robust variance estimator. FINDINGS: Amongst 138 iGBS survivors and 390 non-iGBS children, 38.1% (95% confidence interval [CI]: 30.0% – 46.6%) of iGBS children had any NDI, compared to 21.7% (95% CI: 17.7% - 26.0%) of non- iGBS children, with notable between-site heterogeneity. Risk of moderate/severe NDI was 15.0% (95% CI: 3.4% - 30.8%) among GBS-meningitis, 5.6% (95% CI: 1.5% - 13.7%) for GBS-sepsis survivors. The adjusted risk ratio (aRR) for moderate/severe NDI among iGBS survivors was 1.27 (95% CI: 0.65, 2.45), when compared to non-GBS children. Mild impairment was more frequent in iGBS (27.6% (95% CI: 20.3 – 35.5%)) compared to non-GBS children (12.9% (95% CI: 9.7% - 16.4%)). The risk of emotional-behavioural problems was similar irrespective of iGBS exposure (aRR=0.98 (95% CI: 0.55, 1.77)). INTERPRETATION: Our findings suggest that iGBS disease is on average associated with a higher risk of moderate/severe NDI, however substantial variation in risk was observed between sites and data are consistent with a wide range of values. Our study underlines the importance of long-term follow-up for at-risk neonates and more feasible, standardised assessments to facilitate diagnosis in research and clinical practice. FUNDING: This work was supported by a grant (INV-009018) from the Bill & Melinda Gates Foundation to the London School of Hygiene &Tropical Medicine.
Item Type | Article |
---|---|
Faculty and Department | Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology |
Elements ID | 172533 |
Download
Restricted to: Repository staff only
Filename: GBS_NDI_LMIC_Manuscript_LEClinMed_2feb2022_clean.pdf
Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0